리포좀에 포집된 올리고뉴클레오타이드를 유효성분으로 하는 면역증강 조성물
    33.
    发明公开
    리포좀에 포집된 올리고뉴클레오타이드를 유효성분으로 하는 면역증강 조성물 有权
    含有作为活性成分的脂质体包封的寡核苷酸的免疫组化

    公开(公告)号:KR1020130108672A

    公开(公告)日:2013-10-04

    申请号:KR1020137022689

    申请日:2010-06-16

    Inventor: 권형주

    Abstract: PURPOSE: An immunostimulatory composition containing liposome-encapsulated oligonucleotides as active ingredients is provided to prevent and treat various immune deficiency diseases and to be used as an immunoadjuvant. CONSTITUTION: An immunostimulatory composition contains liposome-encapsulated immunostimulatory oligonucleotides as active ingredients, containing dioleyl phosphatidylethanolamine (DOPE) and cholesteryl hemisuccinate (CHEMS). The immunostimulatory oligonucleotides are CpG oligonucleotides with a nucleotide sequence of sequence number 1 or CpT oligonucleotide with nucleotide sequences selected from sequence numbers 2-49. The immunostimulatory oligonucleotides are CpT oligonucleotides with nucleotide sequences selected among sequence numbers 2, 3, 4, 19, 24, 39, and 46-49.

    Abstract translation: 目的:提供含有脂质体包封的寡核苷酸作为活性成分的免疫刺激组合物,以预防和治疗各种免疫缺陷病,并用作免疫佐剂。 构成:免疫刺激组合物含有脂质体包封的免疫刺激性寡核苷酸作为活性成分,含有二油基磷脂酰乙醇胺(DOPE)和胆固醇半琥珀酸盐(CHEMS)。 免疫刺激性寡核苷酸是具有序列号1的核苷酸序列的CpG寡核苷酸或具有选自序列号2-49的核苷酸序列的CpT寡核苷酸。 免疫刺激性寡核苷酸是具有选自序列号2,3,4,19,24,39和46-49中的核苷酸序列的CpT寡核苷酸。

    리포좀에 포집된 올리고뉴클레오타이드를 유효성분으로 하는 면역증강 조성물
    34.
    发明公开
    리포좀에 포집된 올리고뉴클레오타이드를 유효성분으로 하는 면역증강 조성물 有权
    含有作为活性成分的脂质体包封的寡核苷酸的免疫组化

    公开(公告)号:KR1020120016648A

    公开(公告)日:2012-02-24

    申请号:KR1020117029818

    申请日:2010-06-16

    Inventor: 권형주

    Abstract: PURPOSE: An immunostimulatory composition containing liposome-encapsulated oligonucleotides including DOPE and CHEMS is provided to treat and prevent diseases relating to immunological deficiency. CONSTITUTION: An immunostimulatory composition contains liposome-encapsulated immunostimulatory oligonucleotides as an active ingredient, including DOPE(dioleyl phosphatidylethanolamine) and CHEMS(cholesterylhemisuccinate). The immunostimulatory oligonucleotide is CpG oligonucleotide or CpT oligonucleotide. The composition contains the CpT oligonucleotide including a nucleotide sequence of general formula 1(CTX1X2CTX3X4X5CT) or 2(CTX1X2X3CTX4X5X6CT).

    Abstract translation: 目的:提供含有包含DOPE和CHEMS的脂质体包封的寡核苷酸的免疫刺激组合物,用于治疗和预防与免疫缺陷有关的疾病。 构成:免疫刺激组合物含有脂质体包封的免疫刺激性寡核苷酸作为活性成分,包括DOPE(二油基磷脂酰乙醇胺)和CHEMS(胆固醇硫代琥珀酸盐)。 免疫刺激性寡核苷酸是CpG寡核苷酸或CpT寡核苷酸。 该组合物含有包含通式1的核苷酸序列(CTX1X2CTX3X4X5CT)或2(CTX1X2X3CTX4X5X6CT)的CpT寡核苷酸。

    아토피 피부염 치료 후보 물질의 스크리닝 방법
    35.
    发明授权
    아토피 피부염 치료 후보 물질의 스크리닝 방법 有权
    筛选特应性皮炎候选人的方法

    公开(公告)号:KR100940092B1

    公开(公告)日:2010-02-02

    申请号:KR1020070102084

    申请日:2007-10-10

    Abstract: 본 발명은 피부 감작제에 의해 발현되는 MIP-2 에 의해 유도되는 아토피 피부염을 치료할 수 있는 치료제 개발에 이용할 수 있는 방법에 관한 것으로, 더욱 상세하게는 피부 감작제(예를 들어, DNFB)가 대식세포를 자극하여 키모카인인 MIP-2 (macrophage inflammatory protein-2) 의 발현을 증가시켜 아토피 피부염을 유발하는 과정에서 이를 조절하는 물질을 탐색하는 방법에 관한 것이다.
    DNFB, MIP-2, 아토피 피부염

    아토피 피부염 치료 후보 물질의 스크리닝 방법
    37.
    发明公开
    아토피 피부염 치료 후보 물질의 스크리닝 방법 有权
    用于治疗原发性癌症的候选药物筛选方法

    公开(公告)号:KR1020090036818A

    公开(公告)日:2009-04-15

    申请号:KR1020070102084

    申请日:2007-10-10

    Abstract: A method of screening a candidate material of treating atopic dermatitis is provided to search a treating matter suppressing the expression of MIP-2(macrophage inflammatory protein-2) by a skin sensitizer such as DNFB. A method of screening a candidate material of treating atopic dermatitis comprises the steps of: (a) processing a skin sensitizer to macrophage independently; (b) processing the skin sensitizer and the candidate material to macrophage; and (c) comparing MIP-2 expression at the step (a) and step (b) in macrophage. The MIP-2 protein has an amino acid sequence stated in SEQ ID NO:1. Macrophage is RAW 264.7 cell. The skin sensitizer is selected from the group consisting of DNFB(2,4-dinitrofluorobenzene), DNCB(2,4-dinitrochlorobenzene), and TNBS(2,4,6-trinitrobenzene sulfonic acid).

    Abstract translation: 提供筛选治疗特应性皮炎的候选材料的方法,以通过皮肤敏化剂如DNFB搜索抑制MIP-2(巨噬细胞炎症蛋白-2)表达的治疗物质。 筛选治疗特应性皮炎的候选材料的方法包括以下步骤:(a)将皮肤敏化剂独立地加工成巨噬细胞; (b)将皮肤敏化剂和候选物质加工成巨噬细胞; 和(c)在巨噬细胞中比较步骤(a)和步骤(b)的MIP-2表达。 MIP-2蛋白具有SEQ ID NO:1所示的氨基酸序列。 巨噬细胞是RAW 264.7细胞。 皮肤敏化剂选自DNFB(2,4-二硝基氟苯),DNCB(2,4-二硝基氯苯)和TNBS(2,4,6-三硝基苯磺酸)组。

Patent Agency Ranking